Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Guillermo Garcia-Manero; Ghulam J. Mufti; Pierre Fenaux; Rena Buckstein; Valeria Santini; María Díez-Campelo; Carlo Finelli; Osman Ilhan; Mikkael A. Sekeres; Amer M. Zeidan; Rodrigo Ito; Jennie Zhang; Anita Rampersad; Daniel Sinsimer; Jay T. Backstrom; Uwe Platzbecker; Rami S. Komrokji

doi:10.1182/blood.2021012589

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Guillermo Garcia-Manero^*, Ghulam J. Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Osman Ilhan, Mikkael A. Sekeres, Amer M. Zeidan, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Jay T. Backstrom, Uwe Platzbecker, Rami S. Komrokji

^*Corresponding author for this work

Comprehensive Cancer Centre

Research output: Contribution to journal › Letter › peer-review

16 Citations (Scopus)

Original language	English
Pages (from-to)	624-629
Number of pages	6
Journal	Blood
Volume	139
Issue number	4
DOIs	https://doi.org/10.1182/blood.2021012589
Publication status	Published - 27 Jan 2022

Access to Document

10.1182/blood.2021012589

Cite this

Garcia-Manero, G., Mufti, G. J., Fenaux, P., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Ilhan, O., Sekeres, M. A., Zeidan, A. M., Ito, R., Zhang, J., Rampersad, A., Sinsimer, D., Backstrom, J. T., Platzbecker, U., & Komrokji, R. S. (2022). Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, 139(4), 624-629. https://doi.org/10.1182/blood.2021012589

@article{cf9332833fb44f0db261111c22a71447,

title = "Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial",

author = "Guillermo Garcia-Manero and Mufti, {Ghulam J.} and Pierre Fenaux and Rena Buckstein and Valeria Santini and Mar{\'i}a D{\'i}ez-Campelo and Carlo Finelli and Osman Ilhan and Sekeres, {Mikkael A.} and Zeidan, {Amer M.} and Rodrigo Ito and Jennie Zhang and Anita Rampersad and Daniel Sinsimer and Backstrom, {Jay T.} and Uwe Platzbecker and Komrokji, {Rami S.}",

note = "Funding Information: This study was sponsored by Celgene, a Bristol Myers Squibb Company, Princeton, New Jersey in collaboration with Acceleron Pharma. The authors received writing support in the preparation of this report from Karolina Lech of Excerpta Medica, supported by Bristol Myers Squibb. ",

year = "2022",

month = jan,

day = "27",

doi = "10.1182/blood.2021012589",

language = "English",

volume = "139",

pages = "624--629",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "4",

}

Garcia-Manero, G, Mufti, GJ, Fenaux, P, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Ilhan, O, Sekeres, MA, Zeidan, AM, Ito, R, Zhang, J, Rampersad, A, Sinsimer, D, Backstrom, JT, Platzbecker, U & Komrokji, RS 2022, 'Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial', Blood, vol. 139, no. 4, pp. 624-629. https://doi.org/10.1182/blood.2021012589

TY - JOUR

T1 - Neutrophil and platelet increases with luspatercept in lower-risk MDS

T2 - secondary endpoints from the MEDALIST trial

AU - Garcia-Manero, Guillermo

AU - Mufti, Ghulam J.

AU - Fenaux, Pierre

AU - Buckstein, Rena

AU - Santini, Valeria

AU - Díez-Campelo, María

AU - Finelli, Carlo

AU - Ilhan, Osman

AU - Sekeres, Mikkael A.

AU - Zeidan, Amer M.

AU - Ito, Rodrigo

AU - Zhang, Jennie

AU - Rampersad, Anita

AU - Sinsimer, Daniel

AU - Backstrom, Jay T.

AU - Platzbecker, Uwe

AU - Komrokji, Rami S.

N1 - Funding Information: This study was sponsored by Celgene, a Bristol Myers Squibb Company, Princeton, New Jersey in collaboration with Acceleron Pharma. The authors received writing support in the preparation of this report from Karolina Lech of Excerpta Medica, supported by Bristol Myers Squibb.

PY - 2022/1/27

Y1 - 2022/1/27

UR - http://www.scopus.com/inward/record.url?scp=85123716778&partnerID=8YFLogxK

U2 - 10.1182/blood.2021012589

DO - 10.1182/blood.2021012589

M3 - Letter

C2 - 34758066

AN - SCOPUS:85123716778

SN - 0006-4971

VL - 139

SP - 624

EP - 629

JO - Blood

JF - Blood

IS - 4

ER -

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Access to Document

Other files and links

Cite this